MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE...
March 24 2020 - 8:30AM
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
addressing high unmet medical needs in the treatment of central
nervous system (CNS) disorders, today announced that it will host a
Key Opinion Leader (KOL) call on roluperidone and the treatment of
the negative symptoms of schizophrenia on Tuesday, March 31, 2020.
Dr. Remy Luthringer, Executive Chairman and Chief Executive
Officer of Minerva, will join William T. Carpenter, MD, University
of Maryland, Ofer Agid, MD, University of Toronto, John Kane, MD,
Hofstra University/ Northwell Health System, and Stephen Marder,
MD, UCLA, to discuss the treatment of negative symptoms of
schizophrenia.
In the second quarter of 2020, Minerva expects to announce top
line results from a Phase 3 study with roluperidone in patients
diagnosed with schizophrenia with negative symptoms. Roluperidone
is the only molecule in advanced clinical development that to date
has shown a specific effect on negative symptoms in
schizophrenia.
Tuesday, March 31, 8:00 a.m. Eastern
Time
Domestic: |
877-425-9470 |
International: |
201-389-0878 |
Conference ID: |
13700739 |
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1293503&tp_key=89ca7e9c4b |
Dr. Carpenter is a Professor of the University of Maryland
School of Medicine and past Director of the Maryland Psychiatric
Research Center. He is Past-President of the American College of
Neuropsychopharmacology and chairs the scientific program committee
of the Brain and Behavior Research Foundation. He also chaired the
DSM-V Psychosis Work Group.
Dr. Agid is Clinician Scientist and Psychiatrist in the
Schizophrenia Program and Medical Head, Ambulatory Services and the
Lead Psychiatrist, Partial Hospital Program at the Schizophrenia
Program, Centre for Addiction and Mental Health and Associate
Professor in the Department of Psychiatry at the University of
Toronto.
Dr. Kane is Senior Vice President for Behavioral Health Services
of the Northwell Health System. He is Chairman of Psychiatry and
Professor of Psychiatry and Molecular Medicine at the Donald and
Barbara Zucker School of Medicine at Hofstra/Northwell. He has
chaired review and advisory committees at the NIMH and the Food and
Drug Administration and has served as President of the
Schizophrenia International Research Society and the American
Society of Clinical Psychopharmacology.
Dr. Marder is currently the Director of the Veterans Integrated
Service Network 22 Mental Illness Research, Education Clinical
Center for the Department of Veterans Affairs and the Director of
the Section on Psychosis at the UCLA Neuropsychiatric Institute. He
is a Professor and the Vice Chair for Education at the Semel
Institute for Neuroscience at UCLA.
About Minerva Neurosciences
Minerva’s proprietary compounds include: roluperidone (MIN-101),
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the timing and
scope of future clinical trials and results of clinical trials with
roluperidone (MIN-101); the clinical and therapeutic potential of
this compound; the timing and outcomes of future interactions with
U.S. and foreign regulatory bodies; our ability to successfully
develop and commercialize our therapeutic products; the sufficiency
of our current cash position to fund our operations; and
management’s ability to successfully achieve its goals. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, whether roluperidone will
advance further in the clinical trials process and whether and
when, if at all, it will receive final approval from the U.S. Food
and Drug Administration or equivalent foreign regulatory agencies
and for which indications; whether any of our therapeutic products
will be successfully marketed if approved; whether any of our
therapeutic product discovery and development efforts will be
successful; management’s ability to successfully achieve its goals;
our ability to raise additional capital to fund our operations on
terms acceptable to us; and general economic conditions.
These and other potential risks and uncertainties that could cause
actual results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2019, filed with
the Securities and Exchange Commission on March 9, 2020.
Copies of reports filed with the SEC are posted on our
website at www.minervaneurosciences.com. The forward-looking
statements in this press release are based on information available
to us as of the date hereof, and we disclaim any obligation to
update any forward-looking statements, except as required by
law.
Contact:William B. BoniVP, Investor
Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617)
600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024